Company intelligence / Profile preview
Crinetics Pharmaceuticals
San Diego, California, United Statescrinetics.com ↗
- Ownership
- Public · CRNX
- Development stage
- Other
01
Overview
Crinetics has submitted an NDA for paltusotine for acromegaly treatment. The company has reported positive results from Phase 2 studies of paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia. Multiple programs are advancing through preclinical and clinical development.
- Therapeutic areas
- OncologyEndocrinologyNephrology
- Modalities
- Small moleculesNonpeptide drug conjugates
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Collaboration with Radionetics Oncology
Beyond the preview
Go deeper on Crinetics Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crinetics Pharmaceuticals.